Sarepta Therapeutics
SRPT
13.33
-0.84
-5.93%
Sarepta Therapeutics
US · SRPT
#2853 by market cap
Listed 1970
13.33
-0.84
-5.93%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:54
Quant vs Street three independent views, side by side
StockVane factor grade
F
Momentum strategy signal
Sell
Analyst consensus
Hold
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Deutsche Bank moved from Sell to Hold on 2026-11-10.
Analyst consensus 15 analysts
Hold
Avg price target 22.33 +67.5%
Price target rangecurrent 13.33
Low5.00
Avg22.33
High38.00
Buy 20%
Hold 53%
Sell 27%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-13 | Piper Sandler | -- | Hold | 20.00 |
| 2026-11-10 | Deutsche Bank | -- | Hold | 18.00 |
| 2026-11-09 | Citi | -- | Sell | 13.00 |
| 2026-11-09 | Barclays | -- | Hold | 20.00 |
| 2026-11-06 | Wells Fargo | -- | Buy | 38.00 |
| 2026-11-06 | Piper Sandler | -- | Hold | 20.00 |
| 2026-11-06 | BofA Securities | -- | Sell | -- |
| 2026-11-06 | Baird | -- | Hold | 18.00 |
| 2026-11-06 | Wedbush | -- | Buy | 35.00 |
| 2026-11-06 | Morgan Stanley | -- | Hold | 25.00 |
| 2026-11-06 | H.C. Wainwright | -- | Sell | 5.00 |
| 2026-11-06 | Oppenheimer | -- | Buy | 35.00 |
| 2026-11-05 | Cantor Fitzgerald | -- | Hold | 21.00 |
| 2026-11-02 | BofA Securities | -- | Sell | 18.00 |
| 2026-10-30 | H.C. Wainwright | -- | Sell | 5.00 |
| 2026-10-26 | Wedbush | -- | Buy | 35.00 |
| 2026-10-19 | Piper Sandler | -- | Hold | 20.00 |
| 2026-10-19 | H.C. Wainwright | -- | Sell | 5.00 |
| 2026-10-16 | Wedbush | -- | Buy | 35.00 |
| 2026-10-09 | BofA Securities | -- | Sell | 18.00 |
| 2026-10-05 | H.C. Wainwright | -- | Sell | 5.00 |
| 2026-10-02 | Wells Fargo | -- | Buy | 38.00 |
| 2026-09-30 | Wedbush | -- | Buy | 35.00 |
| 2026-09-30 | J.P. Morgan | -- | Hold | 20.00 |
| 2026-09-28 | William Blair | -- | Hold | -- |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-11-10 | Deutsche Bank | Sell → Hold | 18.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-05 | After close | ±21.00% | +1.42% (in line) |
| 2026/Q2 | 2026-08-05 | After close | ±8.02% | +5.34% (in line) |
| 2026/Q1 | 2026-05-06 | After close | ±9.36% | -9.68% (beat) |
| 2025/Q4 | 2026-02-25 | After close | ±9.75% | -8.01% (in line) |
| 2025/Q3 | 2025-11-03 | After close | ±19.50% | -33.74% (beat) |
| 2025/Q2 | 2025-08-06 | After close | ±12.42% | +10.46% (in line) |
| 2025/Q1 | 2025-05-06 | After close | ±16.88% | -21.45% (beat) |
| 2024/Q4 | 2025-02-26 | After close | ±7.93% | -3.56% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±9.37% | -5.90% (in line) |
| 2024/Q2 | 2024-08-07 | After close | ±10.64% | -2.61% (in line) |
| 2024/Q1 | 2024-05-01 | After close | ±7.20% | -0.21% (in line) |
| 2023/Q4 | 2024-02-28 | After close | ±7.92% | -6.98% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:54:28 · For reference only, not investment advice and not tailored to your situation.
Sarepta Therapeutics discussion 0 comments